EUCTR2006-002072-18-AT进行中（未招募）不适用
A randomized, double-blind, parallel group, placebo controlled, multi center dose ranging study of solifenacin succinate (3 mg, 6 mg and 9 mg) in combination with tamsulosin OCAS 0.4 mg compared with solifenacin succinate monotherapy (3 mg, 6 mg and 9 mg) and tamsulosin OCAS 0.4 mg monotherapy in males with lower urinary tract symptoms - SATUR
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 840
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Male
入选标准
- •Males with LUTS associated with BPH fulfilling the following criteria:
- •Inclusion criteria
- •At study entry:
- •1. Male aged more than 45 years.
- •2. Written informed consent has been obtained.
- •3. Patient is willing and able to complete the micturition diary and questionnaires correctly.
- •4. Voiding symptoms (including incomplete emptying of the bladder, intermittency, weak stream or hesitancy) and storage symptoms (including frequency, urgency or nocturia), diagnosed as LUTS associated with BPH (formerly known as symptomatic BPH) for more than 3 months.
- •5. A total I-PSS score of more than 13.
- •6. A maximum urinary flow rate of more than 4.0 mL/s and = 15.0 mL/s, with a voided volume more than 120 mL during free flow (minimum of 2 flows to be performed).
- •At randomization:
- •7. A total I-PSS score of more than 13.
- •8. Patient continues to meet all inclusion criteria of visit 1.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •At study entry:
- •1. Any significant post void residual volume (PVR > 200 mL) (at least 2 assessments to be performed).
- •2. Evidence of a symptomatic urinary tract infection or a known history or diagnosis of any of the following urinary conditions:
- •- Recurrent symptomatic urinary tract infection
- •- Chronic inflammation such as interstitial cystitis
- •- Stone in bladder or urethra
- •- Previous pelvic radiation therapy
- •- Previous or current malignant disease of the pelvic organs
- •- Previous surgery to the bladder neck or prostate
- •- Bladder neck stenosis
- •- Urethral stricture
- •3. Narrow angle glaucoma, myasthenia gravis, severe gatro-intestinal condition (including toxic megacolon) or patients at risk for these conditions, urinary or gastric retention or any other medical condition which in the opinion of the investigator makes the use of anticholinergics contra-indicated.
- •4. Clinically significant cardiovascular or cerebrovascular diseases within 6 months prior to visit 1, such as myocardial infarction, uncontrolled angina, significant ventricular arrhythmias, heart failure (NYHA class III/IV), a history of orthostatic hypotension or stroke.
- •5. Non-drug treatment for BPH or overactive bladder, including electrostimulation therapy at the start of the study or start of a bladder training program during the 2 weeks prior to or during the study.
- •6. Use of forbidden concomitant medication:
- •Other pharmacological treatment for BPH, such as alpha-AR-antagonists and plant extracts (within the 2 weeks prior to visit 1).
- •5alpha-reductase inhibitors (within the 3 months prior to visit 1).
- •Other drugs which may influence the pharmacodynamic effects of solifenacin or tamsulosin, combined alpha/beta-AR-antagonists, alpha-agonists, cholinergics or anti-cholinergics or CYP 3A4 inhibitors or inducers. This medication should be discontinued ultimately at visit 1 (see Appendix 1 Part A).
- •7. Use of any drugs with cholinergic or anticholinergic side effects, diuretics, oral beta2-agonists or PDE 5 inhibitors (see Appendix 1 Part B). However, long term therapy (>1 month prior to randomization) on a stable dosage of these drugs is permissible.
- •8. Diabetic neuropathy.
- •9. A planned cataract surgery within 30 days after completion of the study.
- •10. Severe renal impairment (including hemodialysis) or moderate or severe hepatic impairment.
- •11. Known or suspected hypersensitivity to solifenacin, other anticholinergics, tamsulosin, other alpha-AR-antagonists, lactose or any of the other inactive ingredients of the study medication.
- •12. Any clinically significant condition, which in the opinion of the investigator makes the patient unsuitable for the trial.
- •13. Participation in any clinical trial within 30 days (or the limit set by national law, whichever is longer) prior to randomization.
- •14. Employees of the Astellas Group, the CROs involved, or the investigator site executing the study.
- •At randomization:
- •15. Patient did not complete the micturition diary or I-PSS questionnaire according to the instructions.
- •16. Total daily urine volume > 3000 mL as verified in the micturition diary.
- •17. Any clinically significant abnormal ECG, which in the opinion of the investigator makes the patient unsuitable for the trial.
- •18. ALAT, ASAT or creatinine outside 2 times the normal range, gamma GT outside 3 times the normal range.
- •19. Any other clinically significant out of the normal range result of urinalysis, biochemistry (including PSA) or hematology, which in the opinion of th
研究者
相似试验
进行中（未招募）
不适用
A randomized, double-blind, parallel group, placebo controlled, multi-center study of fixed dose combinations of solifenacin succinate (6 mg and 9 mg) with tamsulosin hydrochloride OCAS 0.4 mg and tamsulosin hydrochloride OCAS 0.4 mg monotherapy, in male subjects with lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH) with a substantial storage component - Neptuneower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH).MedDRA version: 9.1Level: LLTClassification code 10004446Term: Benign prostatic hyperplasiaLower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH).EUCTR2008-001211-37-DEAstellas Pharma Europe B.V.1,452
进行中（未招募）
1 期
Study to investigate the safety of a drug called osocimab at low and high doses in adult patients with kidney failure requiring regular hemodialysisPrevention of thromboembolic events in ESRD patients on hemodialysis who are at risk for thromboembolic eventsMedDRA version: 21.1Level: LLTClassification code 10049910Term: Thromboembolism prophylaxisSystem Organ Class: 100000004865MedDRA version: 21.1Level: LLTClassification code 10066622Term: Chronic hemodialysisSystem Organ Class: 100000004865MedDRA version: 21.0Level: PTClassification code 10077512Term: End stage renal diseaseSystem Organ Class: 10038359 - Renal and urinary disordersEUCTR2019-003957-27-NLBayer AG750
进行中（未招募）
不适用
A randomized, double-blind, parallel group, placebo-controlled study to assess the efficacy and safety of two doses of oral microencapsulated grass pollen extract administered prior to and during the the grass pollen seasoSeasonal rhino-conjunctivitis due to grass pollen allergyMedDRA version: 9.1Level: LLTClassification code 10001728Term: Allergic rhinoconjunctivitisEUCTR2007-003345-33-DECuralogic A/S680
招募中
3 期
Study of safety, efficacy and tolerability of ianalumab versus placebo, in combination with Standard of care therapy, in participants with active lupus nephritisCTRI/2023/06/053819ovartis Healthcare Pvt Ltd
进行中（未招募）
1 期
A randomized, double-blind, parallel group, placebo controlled, multi center dose ranging study of solifenacin succinate (3 mg, 6 mg and 9 mg) in combination with tamsulosin OCAS 0.4 mg compared with solifenacin succinate monotherapy (3 mg, 6 mg and 9 mg) and tamsulosin OCAS 0.4 mg monotherapy in males with lower urinary tract symptoms - SATUREUCTR2006-002072-18-GBAstellas Pharma Europe B.V.840